Last reviewed · How we verify
Adjuvanted Multimeric-001 250mcg — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Adjuvanted Multimeric-001 250mcg (Adjuvanted Multimeric-001 250mcg) — BiondVax Pharmaceuticals ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Adjuvanted Multimeric-001 250mcg TARGET | Adjuvanted Multimeric-001 250mcg | BiondVax Pharmaceuticals ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Adjuvanted Multimeric-001 250mcg CI watch — RSS
- Adjuvanted Multimeric-001 250mcg CI watch — Atom
- Adjuvanted Multimeric-001 250mcg CI watch — JSON
- Adjuvanted Multimeric-001 250mcg alone — RSS
Cite this brief
Drug Landscape (2026). Adjuvanted Multimeric-001 250mcg — Competitive Intelligence Brief. https://druglandscape.com/ci/adjuvanted-multimeric-001-250mcg. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing